Delve Health Provides the Technology Platform to Design Clinical Trials to Fit a Patient’s Lifestyle
—Not the Other Way Around
A significant number of companies announced delays and cancellations to planned and on-going clinical trials because of COVID-19 lockdowns and social distancing measures. There was a peak of 1,265 trials paused or indefinitely delayed in June 2020—impacting nearly 1,000 companies. Disruptions included delayed initiation or complete withdrawal of planned trials, as well as suspended enrollment or cancellation of on-going trials. The number of disrupted trials has been falling slowly since June 2020, with most current disruptions due to other factors, such as slow enrollment.
Delve Health’s Deployment of Patient Reported Outcomes in Oncology: Pathways to Success and Enhanced Patient Compliance
Delve Health April 30, 2024
Introduction In the intricate field of oncology, understanding patient perspectives—how they feel and function—is crucial. Delve Health stands at the forefront of integrating Patient Reported
Case Study: Leveraging Delve Health Platform for Parkinson’s Study with Wearables Monitoring Dyskinesia
Delve Health March 28, 2024
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by motor symptoms such as tremors, rigidity, and bradykinesia. Clinical trials aimed at developing treatments for PD
Navigating Wear Compliance Issues in Remote Healthcare Monitoring and Clinical Trials
Delve Health March 6, 2024
In recent years, the healthcare industry has seen an exponential increase in the use of wearables for remote monitoring, both in standard healthcare settings and
Digital Endpoints and Patient Outcomes in Clinical Trials: Understanding the Differences and Similarities
Delve Health February 28, 2024
In the rapidly evolving landscape of clinical trials, two terms that are gaining significant traction are “digital endpoints” and “patient outcomes.” Both play critical roles
Enhancing Oncology Clinical Trials with Delve Health: A Blend of Innovation and Care
Delve Health February 7, 2024